https://doi.org/10.55788/7b33c723
Bowel urgency, a common and critical symptom in UC, has sparked interest due to its potential association with fatigue. Dr David Rubin (University of Chicago, IL, USA) presented pooled data from the LUCENT-1 and LUCENT-2 trials, in which he and his colleagues examined the relationship between bowel urgency remission, bowel urgency clinically meaningful improvement, and fatigue [1].
The analysis included 1,706 participants and revealed that the direct effect of bowel urgency remission at week 12 and week 40 accounted for 68.3% and 62.1% of the improvement in the fatigue score, respectively. Notably, improvements in fatigue scores correlated more strongly with bowel urgency remission than with rectal bleeding or stool frequency remission. Similar results were found for clinically meaningful improvement in bowel urgency at week 12 (91.8%) and week 40 (87.4%).
These findings support the association between bowel urgency improvement or remission and fatigue improvement. Moreover, they âprovide us with a better understanding of the difficult challenge of fatigue in our patients,â remarked Dr Rubin.
- Rubin D, et al. Bowel urgency outcomes are associated with improvement in fatigue in patients with moderately-to-severely active ulcerative colitis: a pooled analysis of LUCENT-1 and LUCENT-2 phase 3 trials. Lecture 963, DDW 2023, 6â9 May, Chicago, IL, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Crohnâs disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure Next Article
Environmental and dietary factors can amplify paediatric IBD risk »
« Crohnâs disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure Next Article
Environmental and dietary factors can amplify paediatric IBD risk »
Table of Contents: DDW 2023
Featured articles
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohnâs disease
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Upper GI Disorders: Hot Topics
Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation
Inflammatory Bowel Disease: Novel Developments
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohnâs disease
Environmental and dietary factors can amplify paediatric IBD risk
Ulcerative colitis: bowel urgency remission associated with improvement in fatigue
Crohnâs disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Microbiota in GI Diseases
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection
IBS management: the complex role of dietary fibres
Daily and seasonal fluctuations in the gut microbiome
Spotlight on Colorectal Cancer
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
What is New in Hepatology?
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy